Clinical Trial Update: A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617

View source ↗

Summary

This completed clinical trial update reports patient characteristics, treatment patterns, and outcomes among patients treated with 177Lu-PSMA-617.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Status: COMPLETED